JP2022169589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022169589A5 JP2022169589A5 JP2022124782A JP2022124782A JP2022169589A5 JP 2022169589 A5 JP2022169589 A5 JP 2022169589A5 JP 2022124782 A JP2022124782 A JP 2022124782A JP 2022124782 A JP2022124782 A JP 2022124782A JP 2022169589 A5 JP2022169589 A5 JP 2022169589A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- pharmaceutical composition
- amino acids
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 14
- 102000037865 fusion proteins Human genes 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000025171 antigen binding proteins Human genes 0.000 claims 3
- 108091000831 antigen binding proteins Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- -1 glidant Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188871 | 2016-09-15 | ||
| EP16188871.4 | 2016-09-15 | ||
| JP2019514232A JP7203426B2 (ja) | 2016-09-15 | 2017-09-15 | Ｈｅｒ３に対する抗原結合タンパク質 |
| PCT/EP2017/073328 WO2018050848A1 (en) | 2016-09-15 | 2017-09-15 | Antigen binding protein against her3 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514232A Division JP7203426B2 (ja) | 2016-09-15 | 2017-09-15 | Ｈｅｒ３に対する抗原結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022169589A JP2022169589A (ja) | 2022-11-09 |
| JP2022169589A5 true JP2022169589A5 (https=) | 2023-01-17 |
| JP7638531B2 JP7638531B2 (ja) | 2025-03-04 |
Family
ID=57017956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514232A Active JP7203426B2 (ja) | 2016-09-15 | 2017-09-15 | Ｈｅｒ３に対する抗原結合タンパク質 |
| JP2022124782A Active JP7638531B2 (ja) | 2016-09-15 | 2022-08-04 | Ｈｅｒ３に対する抗原結合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514232A Active JP7203426B2 (ja) | 2016-09-15 | 2017-09-15 | Ｈｅｒ３に対する抗原結合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11008402B2 (https=) |
| EP (1) | EP3512886B1 (https=) |
| JP (2) | JP7203426B2 (https=) |
| KR (1) | KR102469700B1 (https=) |
| CN (1) | CN110167968B (https=) |
| AU (1) | AU2017327769B2 (https=) |
| BR (1) | BR112019005001A2 (https=) |
| CA (1) | CA3033694C (https=) |
| DK (1) | DK3512886T3 (https=) |
| ES (1) | ES3037145T3 (https=) |
| MX (1) | MX2019002664A (https=) |
| WO (1) | WO2018050848A1 (https=) |
| ZA (1) | ZA201901379B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018414456B2 (en) * | 2018-03-22 | 2025-09-11 | Universität Stuttgart | Multivalent binding molecules |
| FI3774859T3 (fi) | 2018-04-11 | 2024-05-24 | Salubris Biotherapeutics Inc | Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| MX2022003507A (es) * | 2019-09-25 | 2022-04-25 | Univ Stuttgart | Modulos de union que comprenden dominios ehd2 modificados. |
| CN115066274A (zh) * | 2019-09-25 | 2022-09-16 | 斯图加特大学 | 三价结合分子 |
| MX2023003304A (es) * | 2020-09-21 | 2023-05-09 | Systimmune Inc | Complejo de union de egfr y metodo de fabricacion y uso del mismo. |
| JP7847132B2 (ja) * | 2020-10-14 | 2026-04-16 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｈｅｒ３抗体と抗ｈｅｒ３抗体薬物複合体及びその医薬用途 |
| WO2023165475A1 (zh) * | 2022-03-03 | 2023-09-07 | 四川科伦博泰生物医药股份有限公司 | Her3结合蛋白及其用途 |
| CN115057946B (zh) * | 2022-06-30 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | 干扰素在制备抗广谱流感病毒和冠状病毒药物中的应用 |
| EP4680648A1 (en) * | 2023-03-17 | 2026-01-21 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-her3 and anti-met antibodies and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU2003218600C1 (en) * | 2002-03-26 | 2009-12-17 | Zensun (Shanghai) Science & Technology Co., Ltd. | ERBB3 based methods and compositions for treating neoplasms |
| EP2896632B1 (en) | 2009-11-13 | 2017-10-25 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing HER-3 associated diseases |
| EP2736928B1 (en) | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
| BR112014012979A2 (pt) * | 2011-11-30 | 2020-10-20 | Genentech, Inc. | mutações erbb3 em câncer |
| CN104093742A (zh) * | 2011-12-05 | 2014-10-08 | 诺华股份有限公司 | 抗her3的结构域iii和结构域iv的表皮生长因子受体3(her3)抗体 |
| US9346890B2 (en) * | 2012-10-25 | 2016-05-24 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ErbB3 |
-
2017
- 2017-09-15 BR BR112019005001-9A patent/BR112019005001A2/pt active Search and Examination
- 2017-09-15 ES ES17768777T patent/ES3037145T3/es active Active
- 2017-09-15 CA CA3033694A patent/CA3033694C/en active Active
- 2017-09-15 WO PCT/EP2017/073328 patent/WO2018050848A1/en not_active Ceased
- 2017-09-15 US US16/326,864 patent/US11008402B2/en active Active
- 2017-09-15 DK DK17768777.9T patent/DK3512886T3/da active
- 2017-09-15 JP JP2019514232A patent/JP7203426B2/ja active Active
- 2017-09-15 KR KR1020197009096A patent/KR102469700B1/ko active Active
- 2017-09-15 EP EP17768777.9A patent/EP3512886B1/en active Active
- 2017-09-15 CN CN201780057182.8A patent/CN110167968B/zh active Active
- 2017-09-15 MX MX2019002664A patent/MX2019002664A/es unknown
- 2017-09-15 AU AU2017327769A patent/AU2017327769B2/en active Active
-
2019
- 2019-03-05 ZA ZA2019/01379A patent/ZA201901379B/en unknown
-
2022
- 2022-08-04 JP JP2022124782A patent/JP7638531B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022169589A5 (https=) | ||
| JP2025111463A5 (https=) | ||
| RU2017139490A (ru) | Конъюгаты лекарственных средств, содержащие антитела против клаудина 18.2 | |
| JP2022079549A5 (https=) | ||
| CN108473563B (zh) | 改进的tnf结合剂 | |
| JP2024501894A5 (https=) | ||
| JP2021531732A5 (https=) | ||
| JP2024520666A5 (https=) | ||
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| JP2025038088A5 (https=) | ||
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| US20230071019A1 (en) | Compositions and methods for reducing off-target toxicity of antibody drug conjugates | |
| JP2023544143A5 (https=) | ||
| JP2021512613A5 (https=) | ||
| JP2021506817A5 (https=) | ||
| JP2023500248A5 (https=) | ||
| WO2024131949A1 (zh) | Anti-cMet抗体、抗体药物偶联物及其制备方法和用途 | |
| CN117645608A (zh) | 抗体药物偶联物及其应用 | |
| CN114106088A (zh) | 基于溴甲基吡嗪的药物偶联物及adc | |
| JP2024517760A (ja) | 抗５ｔ４抗体及びその使用 | |
| JP2024540461A5 (https=) | ||
| US20260035463A1 (en) | Multispecific antibody and use thereof | |
| CN103417965B (zh) | 一种含有抗vegf抗体的药物组合物 | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JP2025505611A5 (https=) |